Phospho-NF-KB p65 (Ser536) Antibody
(Synonyms: Phospho-NF-κB p65; NFKB3; RELA; TF65; Transcription factor p65; p65; NFkB)Based on 8 publication(s) in Google Scholar
Phospho-NF-KB p65 (Ser536) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-NF-KB p65 (Ser536).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
1.Supplied in 1*PBS (pH 7.3), 50% glycerol and 0.5% BSA. Preservative: 0.02% sodium azide.
2.Supplied in PBS containing 150 mM NaCl, 50% glycerol and 0.02% sodium azide, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.
-
Conjugation:
Non-conjugated
Publications Citing Use of MedChemExpress (MCE) Phospho-NF-KB p65 (Ser536) Antibody
More- Adv Sci (Weinh). 2025 Feb;12(8):e2405483. [Abstract]
- J Control Release. 2025 Aug 10:384:113956. [Abstract]
- World J Gastroenterol. 2025 Sep 14;31(34):109825. [Abstract]
- Br J Pharmacol. 2026 Jun;183(11):2761-2782. [Abstract]
- Cell Signal. 2026 Aug:144:112541. [Abstract]
- Surg Endosc. 2026 Jun;40(6):4827-4838. [Abstract]
- Adipocyte. 2025 Dec;14(1):2549456. [Abstract]
- Biomed Pharmacother. 2024 Oct:179:117412. [Abstract]
-
WB
-
WB
-
IHC
-
WB
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
|---|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:100 | 1:50-1:200 |
Product Details
Phospho-NF-KB p65 (Ser536) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-NF-KB p65 (Ser536).
-
Host Rabbit
-
Clonality Polyclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 65 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 60 kDa
Entrez Gene: 5970 Human ; 19697 Mouse ; 309165 Rat
SwissProt: Q04206 Human ; Q04207 Mouse ;
OMIM: 618287 Human
Synthetic phosphopeptide corresponding to residues surrounding Ser 536 of Human NFκB-p65.The exact sequence is proprietary to MCE.
Endogenous
affinity purified
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
1.Supplied in 1*PBS (pH 7.3), 50% glycerol and 0.5% BSA. Preservative: 0.02% sodium azide.
2.Supplied in PBS containing 150 mM NaCl, 50% glycerol and 0.02% sodium azide, pH 7.4.
Please refer to the lot-specific COA for specific buffer information. -
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Pathophysiology-Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain. [Abstract]2025 Feb;12(8):e2405483. PMID: 39716944
Phospho-NF-KB p65 (Ser536) Antibody purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb;12(8):e2405483. [Abstract]
Typical Western blotting bands of proteins associated with MAPK/NF‐κB signaling pathways and macrophage polarization. Western blot analysis showed that APTN significantly attenuated the phosphorylation of MAPK and NF‐κB, reduced iNOS expression, and reinforced Arg1 and CD206 expression in a dose‐dependent manner. anti‐nuclear factor ĸB (NF‐ ĸB) (1:1000, HY‐P80765), anti‐Phospho-NF-KB p65 (Ser536) (1:2000, HY‐P80839) were used in the western blot analysis.
-
J Control Release
Nanomedicine-mediated macrophage polarization enhances the iron-depleting effect of desferrioxamine for breast cancer immunotherapy. [Abstract]2025 Aug 10:384:113956. PMID: 40516575
Phospho-NF-KB p65 (Ser536) Antibody purchased from MedChemExpress. Usage Cited in: J Control Release. 2025 Aug 10:384:113956. [Abstract]
Protein expression levels of NF-κB and P-NF-κB (Phospho-NF-KB p65) in RAW 264.7 cells with different treatments by western blot.
-
World J Gastroenterol
B cell CLL/lymphoma 10 promotes colorectal cancer cell proliferation and regulates cuproptosis sensitivity through the NF-κB signaling pathway. [Abstract]2025 Sep 14;31(34):109825. PMID: 40937457
Phospho-NF-KB p65 (Ser536) Antibody purchased from MedChemExpress. Usage Cited in: World J Gastroenterol. 2025 Sep 14;31(34):109825. [Abstract]
Hematoxylin and eosin staining and IHC for BCL10, DLAT, p65, and Phospho-NF-KB p65 (Ser536) (p-p65 (Ser536)). Scale bars: 50 μm (main panels, 20 × magnification); 20 μm (insets, 40 × magnification). Paraffin-embedded tissues or tumors were serially sectioned at a thickness of 4 µm. The tissue pieces were dewaxed and then heated for 20 minutes at 98 °C in citrate buffer (pH 6.0). Of 3% hydrogen peroxide was added for 15 minutes to inhibit the endogenous peroxidase activity. The presence of these proteins was subsequently ascertained by following a standard protocol and employing anti-DLAT (1:50), anti-BCL10 (1:50), anti-P65 (1:50) or anti-Phospho-NF-KB p65 (Ser536) (HY-P80839, 1:50) antibodies.
-
Br J Pharmacol
Berberine alleviates pre-eclampsia by modulating M1/M2 macrophage polarization and T helper (Th1/Th2) cells cytokine balance. [Abstract]2026 Jun;183(11):2761-2782. PMID: 41671580 -
Cell Signal
B4GALT1 drives osteoarthritis progression by stabilizing IL-1R1 through N-linked glycosylation. [Abstract]2026 Aug:144:112541. PMID: 42002123 -
Surg Endosc
A mechanistic exploration of IL-1β / p38 MAPK / MMP-2 pathway in inguinal hernia: evidence from clinical specimens and in vitro model. [Abstract]2026 Jun;40(6):4827-4838. PMID: 42257932 -
Adipocyte
2025 Dec;14(1):2549456. PMID: 41381093
Phospho-NF-KB p65 (Ser536) Antibody purchased from MedChemExpress. Usage Cited in: Adipocyte. 2025 Dec;14(1):2549456. [Abstract]
Western blot results of Pp65 (Phospho-NF-KB p65 (Ser536)), P65, and CAPG protein levels in sh-Ctrl and sh-Capg cells treated with vehicle control (NC) or 400 μM linoleic acid (LA). In this experiment, the Phospho-NF-κB p65 (Ser536) antibody was incubated with the target protein as the primary antibody overnight at 4°C.
-
Biomed Pharmacother
2024 Oct:179:117412. PMID: 39255734
Verification Images
-
Western blot analysis of extracts from HL-60 (lane 2(20μg) and HL-60 (lane 3(20μg), Human TNF-alpha treated (HY-P7058, 100ng/mL, 3hrs) as indicated, using Phospho-NF-KB p65 (Ser536) (HY-P80839) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Background
-
Function
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Besides its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells. The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection
-
Subcellular Localization
Nucleus; Cytoplasm
-
Isoforms & Post-Translational Modification
NF-κB has 4 isomers: Q04206-1: 60219 Da (predicted); Q04206-2: 58807 Da (predicted); Q04206-3: 59068 Da (predicted); Q04206-4: 59910 Da (predicted).
Ubiquitinated by RNF182, leading to its proteasomal degradation (PubMed:31432514). Degradation is required for termination of NF-kappa-B response. Polyubiquitinated via 'Lys-29'-linked ubiquitin; leading to lysosomal degradation (PubMed:21518757);Monomethylated at Lys-310 by SETD6 (PubMed:21515635). Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes (By similarity);Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities;Phosphorylation at Ser-75 by herpes simplex virus 1/HHV-1 inhibits NF-kappa-B activation;Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation at Lys-310 promotes interaction with BRD4. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2;S-nitrosylation of Cys-38 inactivates the enzyme activity;Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity;Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B;Proteolytically cleaved within a conserved N-terminus region required for base-specific contact with DNA in a CPEN1-mediated manner, and hence inhibits NF-kappa-B transcriptional activity (PubMed:18212740) -
Subunit
Component of the NF-κB p65-p50 complex. Interacts with NFKBIA. Interacts with NFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANK repeats). Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, ELP1 and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH and PHF11. Interacts with ARRB2. Interacts with NFKBIA (when phosphorylated), the interaction is direct; phosphorylated NFKBIA is part of a SCF(BTRC)-like complex lacking CUL1. Interacts with RNF25. Interacts (via C-terminus) with DDX1. Interacts with UFL1 and COMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Directly interacts with MEN1; this interaction represses NFKB-mediated transactivation. Interacts with AKIP1, which promotes the phosphorylation and nuclear retention of RELA. Interacts (via the RHD) with GFI1; the interaction, after bacterial lipopolysaccharide (LPS) stimulation, inhibits the transcriptional activity by interfering with the DNA-binding activity to target gene promoter DNA. Interacts (when acetylated at Lys-310) with BRD4; leading to activation of the NF-κB pathway. Interacts with MEFV. Interacts (via N-terminus) with CPEN1. Interacts with FOXP3. Interacts with CDK5RAP3. Interacts with DHX9; this interaction is direct and activates NF-κB-mediated transcription. Interacts with LRRC25. Interacts with ZBTB7A; involved in the control by RELA of the accessibility of target gene promoters. Directly interacts with DDX3X; this interaction may trap RELA in the cytoplasm, impairing nuclear relocalization upon TNF activating signals.
-
SwissProt ID
-
Synonyms
Phospho-NF-κB p65; NFKB3; RELA; TF65; Transcription factor p65; p65; NFkB
-
Research Field
Cell Biology
Documentation
-
Data Sheet (235 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)